Clinical trials
Oligometastatic Disease clinical trials
Below are recruiting oligometastatic disease clinical trials, each written for real people, not researchers. We’re tracking 30 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06356779Recruiting
Studying local treatment for a few cancer spots
This study is for people with solid tumors that have spread to a few spots (5 or fewer) in the body. It tests whether using a focused treatment like radiation or ablation on those spots can help control the cancer long-term.
Copenhagen, Capital Region of DenmarkAges 18 years+ - NCT05183074Recruiting
MRI-guided focused radiation for prostate cancer
This trial tests a newer way to plan and deliver radiation for prostate cancer using real-time MRI guidance. It may help by aiming high-dose treatment precisely while treating nearby disease and (in some cases) limited metastatic spots.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06652022Recruiting
Radiation plus drugs vs drugs alone for limited spread bladder cancer
This trial tests whether adding targeted radiation to standard drug therapy can help people with a limited number of bladder or urinary tract cancer metastases. It's for those whose cancer has spread to a few spots that can be treated with full coverage radiation.
BeijingAges 18–80 - NCT05679427Recruiting
Surgery-like radiation for limited bone spread
This trial compares two types of highly focused radiation (ablative radiosurgery versus stereotactic radiation in 5 sessions) for people with a small number of metastases in the bone. It aims to find which approach controls these spots with fewer side effects while keeping the treatment “radical,” meaning trying to wipe out the targeted lesions.
Milan, MIAges 18–85 - NCT06918951Recruiting
Stereotactic radiation vs standard radiation for limited cancer spread
This trial compares two types of radiation for people whose cancer has spread to a few new spots while on or after treatment. It tests whether a precise, high-dose radiation approach (stereotactic) works better than the usual palliative radiation for controlling these growing spots.
Surrey, British ColumbiaAges 19 years+ - NCT06180356RecruitingPhase 2
Niraparib after surgery for ovarian cancer with limited spread
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
A CoruñaAges 18 years+ - NCT05917431RecruitingPhase 2
Radiation plus immunotherapy and targeted pills for liver cancer
This Phase 2 trial studies whether a combination of SBRT (focused radiation) plus tislelizumab and regorafenib can control unresectable or limited-spread liver cancer. It may help by attacking tumors in the liver and immune system to improve shrinkage and control of disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05903261Recruiting
Study of targeted radiation for rare cancers with limited spread
This observational study follows people with rare solid tumors and a limited number of metastases treated with a focused radiation technique (SBRT). Doctors want to see outcomes after using a strong, curative-intent radiation dose to all active spots.
Rozzano, MilanAges 18 years+ - NCT06668454Recruiting
Chemoimmunotherapy before surgery for limited spread esophageal cancer
This trial tests a treatment plan that combines chemotherapy with immunotherapy, followed by surgery, for people whose esophageal or stomach cancer has spread to a few areas (oligometastatic). The goal is to see if this approach can shrink the cancer and improve outcomes.
Toronto, OntarioAges 18–80 - NCT05377047Recruiting
Targeted radiation for limited recurrent breast cancer spread
This trial tests whether a precise form of high-dose radiation can control up to 1–5 breast cancer metastases (spread) in a few body areas. It may help by focusing treatment only on visible spots while limiting radiation to the rest of the body.
Gothenburg, Västra GötalandsregionenAges 18 years+ - NCT06593431RecruitingPhase 3
Treating limited spread pancreatic cancer with local therapy
This trial tests whether combining local treatments (like radiation or surgery) with standard care can help people with pancreatic cancer that has spread to only a few spots (oligometastatic disease). The goal is to improve outcomes for this specific group of patients.
Camden, New JerseyAges 18 years+ - NCT06190782RecruitingPhase 3
Local therapy for limited metastatic esophageal cancer
This trial tests whether adding targeted radiation or other local treatments can help people with esophageal cancer that has spread to only a few spots (up to 4) after they've been treated with a PD-1 inhibitor. It aims to control the cancer better and improve outcomes.
ShanghaiAges 18 years+ - NCT06556550RecruitingPhase 2/Phase 3
Targeted radiation for limited cancer spread vs. standard care
This trial tests whether high-precision radiation (SBRT) can improve outcomes for people with up to 5 small, stable metastases from certain cancers, compared to usual palliative care. It is for those whose disease is not growing after current chemotherapy.
Obninsk, Kaluga OblastAges 18 years+ - NCT07079098RecruitingPhase 1
Quick radiation for limited cancer spread
This trial tests a faster way to give radiation to people with a few spots of cancer that have spread. They use a special scan to plan treatment right away, so you may not need a separate planning visit.
Cleveland, OhioAges 18 years+ - NCT05784428Recruiting
Radiation “spot treatments” for a few metastatic or worsening spots
This trial compares giving stereotactic ablative radiotherapy as one larger treatment plan versus several smaller plans for people who have only a few cancer spots (or a few spots that are worsening). It may help control metastatic disease while aiming to protect surrounding healthy organs.
Kelowna, British ColumbiaAges 18 years+ - NCT06439888RecruitingPhase 1/Phase 2
Immune cells plus radiation for limited-stage cancer spread
This trial tests whether giving immune-supporting cells (lymphocytes) alongside focused radiation (SBRT) can help control limited cancer spread. People with 1 to 5 small tumors that can all be radiated within two weeks may be eligible.
LyonAges 18 years+ - NCT06978296Recruiting
HIMARS: Stereotactic radiation for prostate cancer spread
This trial tests adding targeted radiation (SRT) to bone or lymph node metastases in men with prostate cancer that has continued to grow despite hormone therapy, chemo, or other treatments. The goal is to see if radiation can help control the disease and improve outcomes.
Saint-HerblainAges 18 years+ - NCT06373497RecruitingEarly Phase 1
Heart artery health after chest radiation using PET scan
This study looks at how radiation therapy to the chest affects the arteries in your heart. It uses a special PET scan (with a safe radioactive tracer) to check for early signs of inflammation or plaque buildup, which can help doctors find ways to protect your heart during cancer treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT05223803RecruitingPhase 2
Study radiation for early metastatic prostate cancer
This Phase 2 trial tests a radiation-focused approach for people with newly diagnosed (de novo) prostate cancer that has spread to a small number of spots, especially in bone. It aims to see how well the treatment controls the cancer while keeping side effects manageable.
La Jolla, CaliforniaAges 18 years+ - NCT05278052RecruitingPhase 3
Maintenance therapy alone versus radiation plus maintenance for lung cancer
This trial compares standard maintenance treatment versus adding focused radiation to remaining limited (oligometastatic) spots in the body after initial chemotherapy. It aims to see whether treating those limited spots with radiation can improve outcomes without unacceptable side effects.
Mumbai, MaharashtraAges 18–99 - NCT05277844RecruitingPhase 2
Radiation plus targeted pill vs pill alone for EGFR/ALK-NSCLC
This study tests whether adding focused radiation to a targeted cancer pill works better than the pill by itself. It is for people with advanced non-small cell lung cancer (NSCLC) whose tumor has an EGFR or ALK/ROS driver mutation and who have not gotten worse after starting the targeted pill.
Mumbai, MaharashtraAges 18–99 - NCT05352178RecruitingPhase 3
Targeted treatment for few-spread prostate cancer spots
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
LeuvenAges 18 years+ - NCT06121700RecruitingPhase 2
Chemoimmunotherapy and radiation before surgery for limited spread stomach cancer
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
ShanghaiAges 18–75 - NCT06141070RecruitingPhase 3
Adding high-dose radiation to standard treatment for advanced lung cancer
This trial tests whether adding a high, focused dose of radiation to the usual first treatment (chemo and/or immunotherapy) can help people with non-small cell lung cancer that has spread to a limited number of spots (up to 5). The goal is to see if this approach improves how well the treatment works.
GothenburgAges 18 years+
Hear when a new Oligometastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for oligometastatic disease?
- Yes. Clin2 currently lists 30 recruiting oligometastatic disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a oligometastatic disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a oligometastatic disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.